Get started
Author

Aixa E. Soyano‐Muller

Observed names: Aixa E Soyano-Muller, Aixa E. Soyano-Muller, Aixa Soyano-Muller
OpenAlex ID: A5035099790
Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature
2020 · Saranya Chumsri, Ethan S. Sokol, et al. · Journal of the National Comprehensive Cancer Network · 43
Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
2021 · James Sun, Xiaojun Zhong, et al. · Cancer Medicine · 17
PDF
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2019 · Saranya Chumsri, Daniel J. Serie, et al. · Clinical Cancer Research · 13
Iris Metastasis From Breast Cancer Successfully Treated With Abemaciclib and Letrozole
2021 · Lediana Goduni, Noy Ashkenazy, et al. · Retinal Cases & Brief Reports · 7
PDF
Supplemental Table 1 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Table 2 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Figure 1 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Figure 2 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Figure 2 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Table 1 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Table 3 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Table 2 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Figure 1 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Data from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Data from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Supplemental Table 3 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2023 · Saranya Chumsri, Daniel J. Serie, et al.
Abstract OT-15-01: A phase II trial with safety run-in of neoadjuvant therapy with an aromatase inhibitor in combination with durvalumab (MEDI4736) in postmenopausal patients with hormone-receptor-positive (HR+) breast cancer
2021 · Hung T Khong, Dawn N Goodridge, et al. · Cancer Research
Works count: 17
Citation count: 80
H-index: 4
I10-index: 3
Year
Topic
Type